A mystery crypto whale has sold over 1,074 BTC worth $89 million and immediately reinvested the proceeds into Ethereum, purchasing more than 36,159 ETH at an average price of $2,500–$2,530 per ETH. This move highlights a growing trend of large investors swapping Bitcoin for Ethereum, suggesting a long-term strategic shift rather than opportunistic trading. The whale's identity remains unknown, but their activity is tracked by on-chain analysts. This shift comes amid a stagnant broader crypto market, with Ethereum showing stronger recovery than Bitcoin recently, though no clear market direction is established yet.
Bitcoin-to-Ethereum whale activity is the subject, with Pluang market data providing context. As of Oct 14, 2026 23:11 WIB, 6 of 50 major cryptocurrencies rose while 43 fell. Notable movers include SAND at Rp1.001 (-6.70%, 10% Sell / 90% Buy), ONE at Rp28 (-6.33%, 54% Sell / 46% Buy), and XTZ at Rp5.532 (-5.36%, 82% Sell / 18% Buy).
Jefferies has maintained a Buy rating on Big Yellow Group despite recent stock declines, citing the company's strong fundamentals including freehold properties and solid cash flows. Activist investor Ancora, holding over 4% of shares, is pushing Big ...
Fastenal reported strong Q3 2026 earnings, beating analyst expectations with EPS of $0.35 and revenue of $2.46 billion. The company saw a 20% rise in net income to $401.6 million and a 15.5% increase in revenue driven by robust manufacturing demand, ...
Remittix announced the public launch of its RTX token on November 24, 2026, marking the end of its presale phase which raised over $32 million from 40,000 participants. The project is testing its PayFi platform, which enables crypto-to-fiat and fiat-...
The global microbiology testing market is projected to grow rapidly at a compound annual growth rate (CAGR) of approximately 9% from 2026 to 2034, reaching a market size of $13.7 billion by 2034. This growth is driven by the rising prevalence of infe...
H.C. Wainwright raised its price target for Alector from $5.00 to $8.00, maintaining a Buy rating due to progress in its neurodegenerative disease pipeline. Alector develops treatments for Alzheimer's and Parkinson's using its Brain Carrier platform ...
